Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis

By Jönsson B.   Ström O.   Eisman J.   Papaioannou A.   Siris E.   Tosteson A.   Kanis J.  

Osteoporosis International, Vol. 22, Iss. 3, 2011-03 ,pp. : 967-982

Springer Publishing Company

Access to resources Recommend Favorite

Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis

By Josse Robert   Khan Aliya   Ngui Daniel   Shapiro Marla  

Current Medical Research and Opinion, Vol. 29, Iss. 3, 2013-03 ,pp. : 205-216

Informa Healthcare

Access to resources Recommend Favorite

Denosumab: a promising drug for the prevention and treatment of osteoporosis

By Lewiecki E Michael  

Women's Health, Vol. 2, Iss. 4, 2006-07 ,pp. : 517-525

Future Medicine

Access to resources Recommend Favorite

Denosumab-induced Normocalcemic Hyperparathyroidism in a Woman with Postmenopausal Osteoporosis and Normal Renal Function

By  

Current Drug Safety, Vol. 13, Iss. 3, 2018-11 ,pp. : 214-216

Bentham Science Publishers

Access to resources Recommend Favorite

Long-term treatment of osteoporosis in postmenopausal women: a review from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF)

By Cooper C.   Reginster J.-Y.   Cortet B.   Diaz-Curiel M.   Lorenc R.S.   Kanis J.A.   Rizzoli R.  

Current Medical Research and Opinion, Vol. 28, Iss. 3, 2012-03 ,pp. : 475-491

Informa Healthcare

Access to resources Recommend Favorite